Loading clinical trials...
Loading clinical trials...
A Large US Health Insurance Claims Database Will be Used to Estimate the Incidence of Serious Outcomes in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis Treated With Golimumab and Other Types of Biological and Systemic Non Biological Treatments
Conditions
Interventions
systemic non-biological treatments
anti-TNF biologics
+3 more
Start Date
April 14, 2009
Primary Completion Date
May 31, 2015
Completion Date
May 31, 2015
Last Updated
June 25, 2025
NCT07536529
NCT06329401
NCT07048197
NCT07484243
NCT06647069
NCT06841562
Lead Sponsor
Janssen Biotech, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions